本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Oncolytics Biotech Inc

1.16
+0.01000.87%
盘后1.190.0300+2.59%16:59 EDT
成交量:124.16万
成交额:146.48万
市值:1.17亿
市盈率:-4.30
高:1.25
开:1.16
低:1.12
收:1.15
52周最高:1.53
52周最低:0.3258
股本:1.01亿
流通股本:9,362.53万
量比:1.60
换手率:1.33%
股息:- -
股息率:- -
每股收益(TTM):-0.2701
每股收益(LYR):-0.2881
净资产收益率:-249.28%
总资产收益率:-74.56%
市净率:26.60
市盈率(LYR):-4.03

数据加载中...

2025/03/07

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/06/04

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/12

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/03/03

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/03/03

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/05

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/05

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/03/05

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/02

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/24

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/06

年度报告

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/03/05

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/05

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/27

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/22

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/14

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/06

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/04

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/11/12

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/11/12

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]